Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.51 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$23.18M
Enterprise Value-$36.71M
Total Cash (Recent Filing)$70.46M
Total Debt (Recent Filing)$11.28M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 13, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.44
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$7.00Price Target Upside821.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityModest debt levels give management financial flexibility to fund clinical programs and pursue the announced merger without immediate covenant strain. Lower leverage reduces refinancing risk, helping preserve strategic optionality for R&D, licensing or M&A over the next 2–6 months.
Merger Increases Cash RunwayThe announced all-stock combination with Clywedog is a structural change that pools liquidity and extends runway through 2027. This gives time to reach multiple clinical inflection points and reduces near-term external financing pressure, improving the company's ability to execute its development plan.
Focused Pipeline With Clinical ProgressThe strategic shift to immune tolerance and reduced legacy programs concentrates resources on differentiated assets. Ongoing Phase 1/2 progress and planned readouts create durable value drivers: successful clinical milestones can materially de-risk the business and attract partners or licensing opportunities.
Bears Say
Persistent Negative Cash GenerationRepeated negative operating and free cash flow indicate structural cash burn that requires external funding or asset sales. Even with some improvement, continued outflows constrain R&D pacing and increase dilution or financing risk, pressuring execution over the medium term.
Revenue Volatility And Visibility GapSharp revenue swings and a drop to zero in 2025 reflect absence of stable commercial revenue and make forecasting and capital planning difficult. For a clinical-stage biotech, this amplifies reliance on financing milestones and heightens execution risk for sustaining operations long-term.
Nasdaq Minimum Bid Notice / Listing RiskThe Nasdaq deficiency notice creates structural governance and capital-raising risks: potential reverse splits or delisting would hurt liquidity, investor confidence and could complicate future financings or transactions, raising the effective cost of capital and execution risk.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $23.18M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is May 13, 2026 which is in 29 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Mar 13, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.345 by $0.075.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.345. Following the earnings report the stock price went up 4.833%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$7.00
▲(821.05% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
0.19%
Insiders
0.03% Mutual Funds
18.28% Other Institutional Investors
81.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---